GlaxoSmithKline Starts Study Sirukumab
November 25 2015 - 6:04AM
Dow Jones News
LONDON--GlaxoSmithKline PLC (GSK.LN) said Wednesday that it has
commenced a study of a drug used for treating patients with giant
cell arteritis.
The pharmaceutical company has started phase III study of
evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal
antibody.
The study will evaluate the efficacy and safety of two
subcutaneous doses of sirukumab, 100 milligram every two weeks and
50 milligram every four weeks, with a pre-specified tapering dose
of prednisone for the treatment of giant cell arteritis.
Sirukumab is not approved as a treatment for any indication
anywhere in the world.
Shares of GSK at 1032 GMT trading 0.5% higher at 1,350
pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 25, 2015 05:49 ET (10:49 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
